Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Excellence In Execution” Is Key To AstraZeneca’s Bid To Be An Oncology Leader

Executive Summary

Though AstraZeneca is in several ways playing catch up in the oncology space, a strategy built around speed, differentiation and carving out areas of leadership has the firm poised for transformation. Execs are particularly confident the company will become a dominant force as combinations become a larger part of cancer care, pulling from its immunotherapeutic and small molecule pipelines.

You may also be interested in...



AstraZeneca's Cediranib Filing Withdrawal: CHMP Had Two Major Issues

European filing for ovarian cancer candidate cediranib was undone by differences in opinion between AstraZeneca and EMA's CHMP advisory committee in two key areas – the clinical benefit, and compliance with GCP.

Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma

Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.

MedImmune Pulling Ahead As AstraZeneca R&D Engine, Contributing Half Of Pipeline

The large-molecule specialist is delivering on the plan put in place with its 2007 acquisition, with late-stage advances in psoriasis, rheumatoid arthritis, asthma, COPD and lupus, execs say in interview with “The Pink Sheet.” Leading the way for parent company AstraZeneca in cancer immunotherapy, MedImmune says it is well positioned in that widely watched space with clinical candidates in four different mechanisms of action.

Topics

Related Companies

UsernamePublicRestriction

Register

PS056168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel